Skip to content
10-Q

Quarterly Report

BIODESIX INC BDSX

0001193125-26-203960

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 10.11M sh
Shares Diluted Q1 2026 · Mar 31, 2026 9.66M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 7.3M sh
Capex Q1 2026 · Mar 31, 2026 $81K
Capex Q1 2026 · Mar 31, 2025 $74K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$10.17M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.6M
Long Term Debt Q1 2026 · Mar 31, 2026 $50M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $25.57M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $18.99M
Stockholders Equity Q1 2026 · Mar 31, 2026 $9.13M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$2.47M
Stockholders Equity Q1 2026 · Mar 31, 2025 $11.06M
Stockholders Equity Q1 2026 · Dec 31, 2024 $20.88M
Current Liabilities Q1 2026 · Mar 31, 2026 $14.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $17.44M
Total Liabilities Q1 2026 · Mar 31, 2026 $85.51M
Total Liabilities Q1 2026 · Dec 31, 2025 $89.94M
Current Assets Q1 2026 · Mar 31, 2026 $40.91M
Current Assets Q1 2026 · Dec 31, 2025 $32.52M
Total Assets Q1 2026 · Mar 31, 2026 $94.64M
Total Assets Q1 2026 · Dec 31, 2025 $87.48M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.81
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$1.52
Eps Basic Q1 2026 · Mar 31, 2026 −$0.81
Eps Basic restated Q1 2026 · Mar 31, 2025 −$1.52
Sga Expense Q1 2026 · Mar 31, 2026 $24.26M
Sga Expense Q1 2026 · Mar 31, 2025 $20.45M
Rd Expense Q1 2026 · Mar 31, 2026 $3.29M
Rd Expense Q1 2026 · Mar 31, 2025 $2.87M
Net Income Q1 2026 · Mar 31, 2026 −$7.79M
Net Income Q1 2026 · Mar 31, 2025 −$11.1M
Operating Income Q1 2026 · Mar 31, 2026 −$6.2M
Operating Income Q1 2026 · Mar 31, 2025 −$9.14M
Revenue Q1 2026 · Mar 31, 2026 $25.56M
Revenue Q1 2026 · Mar 31, 2025 $17.96M